title: Advanced malignant pleural or peritoneal effusion in patients treated with recombinant adenovirus p53 injection plus cisplatin.
abstract: The aim of this study was to evaluate the efficacy of recombinant adenovirus p53 agent (rAd-p53) injection combined with cisplatin (CDDP) for the treatment of malignant pleural or peritoneal effusion. After puncture drainage, patients in the treatment group (n = 27) received intracavitary administration of rAd-p53 (2 x 10(12) virus particles) once a week for 4 weeks. At 48 h after each rAd-p53 injection, patients were given intracavitary administration of cisplatin 60 mg/m(2). This administration procedure continued once a week for 4 weeks. The control group (n = 21) received the same intracavitary therapy as the treatment group but without rAd-p53 therapy. Efficacy was evaluated by clinical observations, computed tomography, tumour markers, Karnofsky score and short-term follow-up. The total effective rates for the treatment group (63.0%) were significantly higher than for the control group (42.9%), suggesting that the treatment group benefited over the control group. In conclusion, rAd-p53 therapy is a safe and effective treatment for advanced malignant pleural or peritoneal effusion.
authors.affiliation: Department of Medical Oncology, Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
authors.forename: M
authors.initials: M
authors.lastname: Dong
authors.forename: X
authors.initials: X
authors.lastname: Li
authors.forename: L-J
authors.initials: LJ
authors.lastname: Hong
authors.forename: R
authors.initials: R
authors.lastname: Xie
authors.forename: H-L
authors.initials: HL
authors.lastname: Zhao
authors.forename: K
authors.initials: K
authors.lastname: Li
authors.forename: H-H
authors.initials: HH
authors.lastname: Wang
authors.forename: W-D
authors.initials: WD
authors.lastname: Shin
authors.forename: H-J
authors.initials: HJ
authors.lastname: Shen
mesh_terms: D000260:Adenoviruses, Human / Q000235:genetics; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001201:Ascites / Q000097:blood / Q000473:pathology / Q000628:therapy*; D001202:Ascitic Fluid / Q000187:drug effects / Q000473:pathology; D014408:Biomarkers, Tumor / Q000097:blood; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D016158:Genes, p53; D015316:Genetic Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D016066:Pleural Effusion, Malignant / Q000097:blood / Q000473:pathology / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D011994:Recombinant Proteins; D016159:Tumor Suppressor Protein p53; D002945:Cisplatin